Drug Topics May 2020

Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast Cancer

May 13, 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.

A Conversation About Cancer Care During COVID-19

April 10, 2020

In a video interview with Drug Topics®, Robert Brunault, PharmD, a clinical pharmacy specialist of hematology and oncology at Rhode Island Hospital and Lifespan Cancer Institute, answers questions about how the COVID-19 pandemic affects patients undergoing treatment for cancer.